- Next generation bio-therapeutics include innovative antibody-based therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, and Fc-engineered antibodies, which offer enhanced specificity, potency, and safety compared to traditional biologics
- The market is witnessing strong momentum due to the growing pipeline of advanced biologics, increasing approvals of next-gen antibody drugs, and rising investments in biologic R&D
- Oncology remains the dominant therapeutic application segment, driven by the high global burden of cancer and the increasing adoption of targeted next-gen therapies
- North America leads the global market owing to a strong biotechnology sector, well-established healthcare infrastructure, and growing approvals of innovative biologics by regulatory bodies like the FDA
- Asia-Pacific is expected to be the fastest-growing region during the forecast period, fueled by expanding biopharma investments, increasing access to advanced therapies, and rising awareness about biologic treatments
- Antibody-drug conjugates (ADCs) are projected to dominate the market’s technology segment with 42.6% share, due to their precision in delivering cytotoxic drugs directly to tumor cells, minimizing systemic side effects and enhancing treatment outcomes
